Vida Therapeutics Inc

About Us At viDA Therapeutics Inc, we are pioneering a new class of targeted therapies for dermatology and ocular health by harnessing insights into the role of granzymes in aging, inflammation, and tissue damage. Our mission is simple yet powerful: to improve patient quality of life by developing first-in-class inhibitors of Granzyme B (GzmB) and Granzyme K (GzmK). Research led by our scientific co-founder, Dr. David Granville, has shown that excessive extracellular granzyme activity drives loss of skin integrity, impaired wound healing, itch, scarring, and age-related tissue degeneration. By targeting these proteases, our programs are designed to restore skin barrier function, preserve extracellular matrix structure, and protect vision. Our pipeline includes both novel chemical entities (NCEs) such as VDA001, a potent topical GzmB inhibitor now advancing through IND-enabling studies, and plant-derived natural health products (NHPs) for rapid entry into medical skincare and cosmeceuticals. We are advancing opportunities in autoimmune and age-related skin disease, ocular disorders including age-related macular degeneration (AMD) and Fuchs Endothelial Corneal Dystrophy (FECD), and broader inflammatory indications. Supported by competitive grants, industry collaborations, and a strong intellectual property portfolio, viDA Therapeutics is building a differentiated dermatology and ocular franchise. We are committed to partnering with investors, clinicians, and consumer health leaders to deliver transformative therapies to patients worldwide. Follow us for updates on our progress as we bring science-driven innovation to the future of skin and eye health.